[
    [
        {
            "time": "",
            "original_text": "复星医药(02196)：汉贝泰?用于转移性结直肠癌、非小细胞肺癌治疗获上市注册批准",
            "features": {
                "keywords": [
                    "复星医药",
                    "汉贝泰",
                    "转移性结直肠癌",
                    "非小细胞肺癌",
                    "上市注册批准"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "复星医药(02196)：汉贝泰?用于转移性结直肠癌、非小细胞肺癌治疗获上市注册批准",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "复星医药：控股子公司获药品注册批准",
            "features": {
                "keywords": [
                    "复星医药",
                    "控股子公司",
                    "药品注册批准"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "复星医药：控股子公司获药品注册批准",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "复星医药(600196.SH)：用于转移性结直肠癌及晚期、转移性或复发性非小细胞肺癌治疗的汉贝泰?获批上市",
            "features": {
                "keywords": [
                    "复星医药",
                    "汉贝泰",
                    "转移性结直肠癌",
                    "非小细胞肺癌",
                    "获批上市"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "复星医药(600196.SH)：用于转移性结直肠癌及晚期、转移性或复发性非小细胞肺癌治疗的汉贝泰?获批上市",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "复星医药最新公告：贝伐珠单抗注射液获药品注册批准",
            "features": {
                "keywords": [
                    "复星医药",
                    "贝伐珠单抗注射液",
                    "药品注册批准"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "复星医药最新公告：贝伐珠单抗注射液获药品注册批准",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "复星医药：贝伐珠单抗注射液获药品注册批准",
            "features": {
                "keywords": [
                    "复星医药",
                    "贝伐珠单抗注射液",
                    "药品注册批准"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "复星医药：贝伐珠单抗注射液获药品注册批准",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "中山公用：公司暂未收到大股东中汇集团意向购买复星集团计划减持的公司股份的相关消息",
            "features": {
                "keywords": [
                    "中山公用",
                    "中汇集团",
                    "复星集团",
                    "减持",
                    "股份"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "中山公用：公司暂未收到大股东中汇集团意向购买复星集团计划减持的公司股份的相关消息",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "华润三九(000999)：员工股权激励方案终出台 建立长效激励机制 彰显公司发展信心",
            "features": {
                "keywords": [
                    "华润三九",
                    "员工股权激励",
                    "长效激励机制",
                    "发展信心"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华润三九(000999)：员工股权激励方案终出台 建立长效激励机制 彰显公司发展信心",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]